Nearly a decade of research to solve a common eye ailment paid off for Encore Vision in Fort Worth.
The company, founded by Alcon Laboratories veteran Bill Burns, has been acquired by pharmaceutical giant Novartis, the Swiss company that also owns Alcon.
The acquisition comes just as Encore Vision prepares to bring a topical eye treatment to market. Financial details were not disclosed.
The eye drops will be used to treat presbyopia, a condition that most people get as they age that makes it harder for them to focus their eyes. Clinical tests have shown it can improve vision over three months.
Encore Vision is based at TECH Fort Worth, a nonprofit that helps entrepreneurs grow their companies. Encore Vision received the largest single investment, $1.25 million, from the Cowtown Angels, the investors who founded TECH Fort Worth.
Delivering what’s new and next in Dallas-Fort Worth innovation, every day. Get the Dallas Innovates e-newsletter.
R E A D N E X T
-
What does diversity, equity, and inclusion look like in real life? How can organizations become diverse, inclusive, and equitable, and make it work? How can they make it last? A three-part virtual workshop—set for Jan. 19, Jan. 26, and Feb. 2—aims to present a blueprint on just that, featuring leaders who have seen successful DEI programs launched, and who will discuss key elements that made them successful. On Jan. 19, three nationally renowned leaders in diversity will kick off the seminars in a discussion titled “A Holistic DEI Approach in Academia”: Dallas ISD Superintendent Michael Hinojosa, who oversees one of…
-
The Bedford-based biotech will use the capital from the National Eye Institute of the National Institutes of Health to advance its gene therapy that treats age-related macular degeneration. Earlier this summer, Nanoscope Therapeutics announced it successfully treated 11 patients who were blinded by advanced retinitis pigmentosa.
-
Nanoscope Therapeutics successfully treated 11 patients blinded by advanced retinitis pigmentosa (RP). A single intravitreal injection produced positive results that persisted through one year. The startup plans a Phase 2b trial this summer and plans to develop gene therapies to treat more common retinal diseases—like dry age-related macular degeneration.
-
Panna Sharma has had a hand in four IPOs. The latest was finalized during the middle of COVID for his clinical stage biopharmaceutical oncology firm, Lantern Pharma. Now, he shares the phases to transforming a young private company into the next public success story.
